In the present study we show that the avidity of serum anti-TF IgG is not increased in cancer, in contrast to that of IgM (Figure 2, Table 2), indicating that IgG is not involved in cancer-related changes of TF-specific antibody avidity. This evidence concerns the gene CD40LG and cancer.